Trial Profile
An Open-Label Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 18 Sep 2015 Status changed from completed to discontinued as of 18 Sep 2015, as reported by ClinicalTrials.gov.
- 08 May 2015 New trial record